Gene dreams : Wall Street, academia, and the rise of biotechnology / Robert Teitelman.

  • Teitelman, Robert.
Date:
[1989], ©1989
Catalogue details

Licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

Credit: Gene dreams : Wall Street, academia, and the rise of biotechnology / Robert Teitelman. Source: Wellcome Collection.

    253/264 (page 235)
    Index March of Dimes, 16 Marx, Leo, 5, 6 Mayo Clinic, 190 M. D. Anderson, 17, 69-70 Medawar, Peter, 15, 51 Medical Research Council Laboratory of Molecular Biology (MRC), 19, 20 Medicare, 9, 120, 121 Melanoma, 37 Melton, John, 180 Memorial Hospital, 31 Memorial Sloan-Kettering, 17, 30, 37, 81; interferon laboratory at, 32, 106 Merck, 15, 69, 115, 183, 207, 221n8 Merrill Lynch, 36, 105 Methotrexate, 33 Microbiology, 158-59 Microcomputers, 22 Microprocessor, 187 Microtrak chlamydia test, 110, 121, 132, 159; and the Legionnaires' test, compar¬ ison of, 133, 134 Mikulski, Stanislaw, 100 Miller, Linda, 129, 191 Milstein, Cesar, 19-20, 21, 107, 126 MIT (Massachusetts Institute of Technol¬ ogy), 14, 59, 89, 149 Mitchison, Avrion, 81 MKS Research, Inc., 93, 94 Monoclonal antibodies, 7, 19, 20, 37, 122; article on, in Science, 131; article on, in The Sciences, 37; and diagnostics, 106, 109-10, 131; Genetic Systems and, 80, 86, 88; and hybridomas, 107-8; and Hy- britech, 78; and magic bullets, 37-38, 75-76; Nowinski and, 39, 80; and On¬ cogen, 152; see also Antibodies Monoclonal Antibodies (company), 110 Moore, Gordon, 206 Morgan Stanley, 161 Muller & Company, 36, 44, 45, 93 Mutations, 19 Nature, 20 NeoRx (company), 194, 198 New England ]ournal of Medicine, 188 New England Nuclear, 87 Newsweek, 32, 73 New York Magazine, 32 New York Times, 30 New York Times Magazine, 31 NIH 3T3, 56, 150 Nixon, Richard M., 8, 14, 30, 32, 68 Nova Pharmaceuticals, 195-96 Nowinski, Robert, 37, 38-43, 70, 80-90, 106, 210; and AIDS, 139, 160-61; and Applied Biosystems, deal with, 135-37; and Carter, 212-13; character of, 80-84, 88, 137-38; on diagnostics, 131, 152; and Genetic System's financial decline, 155, 160-61; managerial style of, 164-73; on monoclonals as diagnostic tools, in Sci¬ ence, 131; as the mouse doctor, 107, 109; and Syntex, dealings with, 74, 171- 73, 174, 177-78, 181 Noyce, Robert, 206 NSTT (nonspecific tumor toxic), 93-97,102 Nutrition, 68 NYU Medical Center, 31 Office of Technology Assessment, 26, 73 Oncogen, 92, 105, 132, 152, 178; and Bris¬ tol-Myers, 162, 165, 184, 185 Oncogenes, 58, 59, 63, 67, 123, 147-54; sar¬ coma, 60, 61; see also Oncogen Oncostatin, 66-67, 92, 213 ONKEM, 89 Operation Neutral, 135, 177 Oraflex, 175 Oras, Andrew, 93-94, 97 Order, Stanley, 124 Orion Pictures, 30 Ortho Diagnostic, 115, 119, 121 Osteogenic sarcoma, 29, 33 National Academy of Science, 183, 218n7 National Cancer Institute (NCI), 16, 17, 18, 30; and AIDS, 138-39; grant reviews by, 42; and immunotherapy, 31; and inter¬ feron, 32; and Pannon research, 101; To- daro and, 55, 57, 59, 64-70, 89, 149, 152- 54, 183 National Distillers, 24 National Institutes of Health (NIH), 8, 16, 17, 208; Lasker and, 29, 30; Todaro at, 56-57, 148; and the viral oncology pro¬ gram, 67 National OTC Stock ]ournal, 99 National Semiconductor, 205 PaineWebber, 12, 106, 128-29, 191 Pannon,97-101 Papadopoulos, Stelios, 191, 192 Pasteur Institute, 138, 140, 170 Patents, 9, 170, 190, 194, 224n5, 225n4 Peer-review system, 8 Penicillin, 15, 34 Pepsico, 187 Personal-computer boom, 23, 186-87 Pharmaceutical Manufacturers Associa¬ tion (PMA), 142 Physics, particle, 149 235